Clinical trials recruiting in Esplugues de Llobregat, Spain

Phase breakdown

Conditions recruiting in Esplugues de Llobregat, Spain

Recruiting trials in Esplugues de Llobregat, Spain

• A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
  NCT07227857 · Phase: Phase 1, Phase 2 · Ages: 2 Years to 12 Years · Sex: All (male and female)
• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
  NCT04844606 · Phase: Phase 3 · Ages: 2 Years to 19 Years · Sex: All (male and female)
• A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
  NCT07253285 · Phase: Phase 3 · Ages: 8 Years to 18 Years · Sex: All (male and female)
• A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
  NCT05076175 · Phase: Phase 2, Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
  NCT05970172 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
  NCT06131840 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
  NCT04779320 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
  NCT06461897 · Phase: Phase 3 · Ages: 2 Years to 11 Years · Sex: All (male and female)
• A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
  NCT06100744 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female)
• A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
  NCT04772079 · Phase: Phase 3 · Ages: 4 Years to 18 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
  NCT07227454 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
  NCT06979453 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female)
• A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
  NCT07192952 · Phase: Phase 3 · Ages: Up to 18 Years · Sex: All (male and female)
• A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
  NCT05457283 · Phase: Phase 3 · Ages: 1 Year to 18 Years · Sex: All (male and female)
• A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
  NCT07188805 · Phase: Phase 3 · Ages: 6 Months to 17 Years · Sex: All (male and female)
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
  NCT05835310 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female)
• Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
  NCT06332534 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
  NCT05714085 · Phase: Phase 2, Phase 3 · Ages: 29 Days to 17 Years · Sex: All (male and female)
• Integrative Diagnosis for SCD and Other RADs
  NCT07206095 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
  NCT05219617 · Phase: Phase 3 · Ages: 4 Years to 55 Years · Sex: All (male and female)
• Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
  NCT06408259 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Esplugues de Llobregat, Spain?

21 recruiting trials have at least one study site in Esplugues de Llobregat, Spain.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.